Elanco Animal Health (ELAN) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ELAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELAN, but not buy additional shares or sell existing shares.
View ELAN analyst ratings or view top-rated stocks.

6 equities research analysts have issued twelve-month target prices for Elanco Animal Health's stock. Their ELAN share price forecasts range from $9.50 to $20.00. On average, they expect the company's stock price to reach $15.10 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price.
View analysts price targets for ELAN or view top-rated stocks among Wall Street analysts.

Elanco Animal Health's stock was trading at $12.22 at the beginning of 2023. Since then, ELAN stock has decreased by 7.7% and is now trading at $11.28.
View the best growth stocks for 2023 here.

Elanco Animal Health saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 10,360,000 shares, an increase of 10.2% from the August 15th total of 9,400,000 shares. Based on an average trading volume of 5,800,000 shares, the days-to-cover ratio is presently 1.8 days.
View Elanco Animal Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ELAN earnings forecast.

Elanco Animal Health Incorporated (NYSE:ELAN) announced its quarterly earnings results on Monday, August, 7th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.13. The business earned $1.06 billion during the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a positive trailing twelve-month return on equity of 6.93% and a negative net margin of 2.24%. Elanco Animal Health's revenue was down 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.36 EPS.

ETFs with the largest weight of Elanco Animal Health (NYSE:ELAN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), First Trust Health Care AlphaDEX Fund (FXH), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), Principal Healthcare Innovators ETF (BTEC), VanEck Agribusiness ETF (MOO) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Elanco Animal Health updated its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of $0.08-$0.13 for the period, compared to the consensus earnings per share estimate of $0.16. The company issued revenue guidance of $1.02 billion-$1.06 billion, compared to the consensus revenue estimate of $1.04 billion.

169 employees have rated Elanco Animal Health Chief Executive Officer Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), Walt Disney (DIS), Johnson & Johnson (JNJ), AT&T (T), Cisco Systems (CSCO), CVS Health (CVS) and Bristol-Myers Squibb (BMY).

(ELAN) raised $1.4 billion in an initial public offering (IPO) on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

Elanco Animal Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.51%), Shapiro Capital Management LLC (4.14%), Black Creek Investment Management Inc. (2.79%), State Street Corp (1.97%), Goldman Sachs Group Inc. (1.83%) and Geode Capital Management LLC (1.36%). Insiders that own company stock include Aktiengesellschaft Bayer, Art A Garcia, Elanco Animal Health Inc, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, R David Hoover and Rajeev A Modi.
View institutional ownership trends.

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ELAN stock can currently be purchased for approximately $11.28.

Elanco Animal Health (NYSE:ELAN) has a market capitalization of $5.56 billion and generates $4.42 billion in revenue each year. The company earns $-78,000,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

The company employs 9,000 workers across the globe.

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The official website for the company is www.elanco.com. The company can be reached via phone at (877) 352-6261 or via email at kanaga_tiffany@elanco.com.